Loading company…
OncoInsight develops NK and CAR-NK cell therapy candidates for cancer.
Founded in 2017 and based in Seoul, OncoInsight develops immune cell therapies using its CAR-NK platform and stem cell-derived NK cell technology. Its pipeline includes OI-101 for lung cancer and OI-201 and OI-203 for gastric cancer and triple-negative breast cancer.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in